Pricing Log in Create free account

ADMA Biologics Inc (ADMA) vs Denali Therapeutics Inc. (DNLI)

ADMA Biologics Inc and Denali Therapeutics Inc. are both Biotechnology companies. ADMA Biologics Inc and Denali Therapeutics Inc. are of similar size ($3.2B and $3.0B). Denali Therapeutics Inc. has negative trailing earnings, so its P/E is not meaningful; ADMA Biologics Inc trades at 16.1×. ADMA Biologics Inc grew revenue faster over the last twelve months: 6.26% against −93.4%. ADMA Biologics Inc has the higher net margin (35.1% vs −1,388.2%) and the higher return on invested capital (29.5% vs −80.0%). Across the 18 metrics below, ADMA Biologics Inc leads on 13 and Denali Therapeutics Inc. on 5.

Valuation

Metric ADMA DNLI Biotechnology median
P/E 16.14 n/m 10.60
P/S 5.52 167.35 9.40
P/B 6.53 4.09 2.13
Price to free cash flow 21.59 n/m 25.18
EV/EBITDA 11.78 n/m 0.66
EV/Sales 5.66 144.80 9.02
Earnings yield 6.20% (8.59%) (32.88%)
Free cash flow yield 4.63% (11.87%) (23.13%)

Profitability

Metric ADMA DNLI Biotechnology median
Gross margin 68.53% 98.74% 68.51%
Operating margin 46.47% (2,348.95%) 0.00%
Net margin 35.14% (1,388.24%) 0.00%
Free cash flow margin 25.54% (1,986.81%) 0.00%
Return on equity 41.95% (33.94%) (51.96%)
Return on assets 28.04% (27.20%) (46.06%)
Return on invested capital 29.48% (80.00%) 0.00%

Growth

Metric ADMA DNLI Biotechnology median
Revenue growth (TTM) 6.26% (93.40%) 6.76%
EPS growth (last fiscal year) (25.93%) (15.56%) 29.88%
Revenue growth, 5-year CAGR 64.60% 20.67% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ADMA DNLI Biotechnology median
Debt to equity 0.45 0.01 0.00
Current ratio 6.04 6.21 4.97
Net debt to EBITDA (0.06) 1.56 1.01

Dividend

Metric ADMA DNLI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ADMA DNLI Biotechnology median
Market cap 2.96b 3.16b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack